Have a feature idea you'd love to see implemented?
Let us know!
IGMS IGM Biosciences Inc
Price (delayed)
$6.4
Market cap
$380.57M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.61
Enterprise value
$383.36M
Headquartered in Mountain View, California, IGM Biosciences is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. Since 2010, IGM Biosciences has worked to overcome the manufacturing
Highlights
IGMS's revenue has surged by 58% year-on-year
IGM Biosciences's gross profit has surged by 58% YoY
IGM Biosciences's equity has plunged by 69% YoY and by 35% from the previous quarter
IGM Biosciences's quick ratio has decreased by 45% YoY and by 27% QoQ
Key stats
What are the main financial stats of IGMS
Market
Valuations
Earnings
Shares outstanding
59.46M
Market cap
$380.57M
Enterprise value
$383.36M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.81
Price to sales (P/S)
133.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
131.38
Revenue
$2.92M
Gross profit
$2.92M
Net income
-$219.84M
EBIT
-$219.6M
EBITDA
-$205.17M
Free cash flow
-$172.58M
Per share
Balance sheet
Liquidity
EPS
-$3.61
EPS diluted
-$3.61
Free cash flow per share
-$2.85
Book value per share
$1.33
Revenue per share
$0.05
TBVPS
$5.02
Total assets
$304.51M
Total liabilities
$225.56M
Debt
$45.86M
Equity
$78.95M
Working capital
$185.67M
Debt to equity
0.58
Current ratio
5.22
Quick ratio
4.98
Net debt/EBITDA
-0.01
Margins
Efficiency
Dividend
EBITDA margin
-7,031.2%
Gross margin
100%
Net margin
-7,534%
Operating margin
-8,043.8%
Return on assets
-61%
Return on equity
-155.4%
Return on invested capital
-76.9%
Return on capital employed
-84.3%
Return on sales
-7,525.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IGMS stock price
How has the IGM Biosciences stock price performed over time
Intraday
-1.69%
1 week
-14.44%
1 month
-28.01%
1 year
-23.44%
YTD
-22.98%
QTD
-61.31%
Financial performance
How have IGM Biosciences's revenue and profit performed over time
Revenue
$2.92M
Gross profit
$2.92M
Operating income
-$234.72M
Net income
-$219.84M
Gross margin
100%
Net margin
-7,534%
IGMS's revenue has surged by 58% year-on-year
IGM Biosciences's gross profit has surged by 58% YoY
IGMS's operating margin is up by 42% year-on-year
IGM Biosciences's net margin has increased by 41% YoY
Growth
What is IGM Biosciences's growth rate over time
Valuation
What is IGM Biosciences stock price valuation
P/E
N/A
P/B
4.81
P/S
133.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
131.38
The EPS is up by 27% year-on-year
IGM Biosciences's equity has plunged by 69% YoY and by 35% from the previous quarter
The stock's P/B is 11% below its 5-year quarterly average of 5.4 and 11% below its last 4 quarters average of 5.4
IGMS's revenue has surged by 58% year-on-year
IGMS's price to sales (P/S) is 45% less than its last 4 quarters average of 241.5
Efficiency
How efficient is IGM Biosciences business performance
IGMS's return on equity has dropped by 69% year-on-year and by 31% since the previous quarter
The return on sales is up by 41% year-on-year
The ROA has contracted by 23% YoY and by 12% from the previous quarter
The return on invested capital has declined by 8% year-on-year and by 2.8% since the previous quarter
Dividends
What is IGMS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IGMS.
Financial health
How did IGM Biosciences financials performed over time
The total assets is 35% greater than the total liabilities
IGM Biosciences's quick ratio has decreased by 45% YoY and by 27% QoQ
IGM Biosciences's current ratio has decreased by 44% YoY and by 26% QoQ
IGM Biosciences's debt is 42% less than its equity
IGMS's debt to equity has soared by 81% QoQ
IGM Biosciences's equity has plunged by 69% YoY and by 35% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.